moderately emetogenic chemotherapy. Support
Care Cancer 2017;25(1):85–92.
52 Cass AS et al. Infusion reactions following
administration of intravenous rolapitant at an
academic medical center. J Oncol Pharm Pract
2018;22:1078155218808084.
53 Varubi (rolapitant) Injectable Emulsion. US
Food and Drug Administration. www.fda.gov/
drugs/postmarket-drug-safety-information-
patients-and-providers/varubi-rolapitant-
injectable-emulsion (accessed June 2019).
54 Ito Y et al. Placebo-controlled, double-blinded
Phase III study comparing dexamethasone on
day 1 with dexamethasone on days 1 to 3 with
combined neurokinin-1 receptor antagonist and
palonosetron in high-emetogenic chemotherapy.
J Clin Oncol 2018;36:1000–6.
55 Antonarakis ES et al. Prophylaxis of acute
chemotherapy-induced nausea and vomiting
in children with cancer: what is the evidence?
Pediatr Blood Cancer 2004;43(6):651–8.
56 Metoclopramide. In: UpToDate, UpToDate,
Waltham, MA, 2017. www.uptodate.com/home/
index.html (accessed July 2018).
57 Alizapride. Summary of product characteristics.
www.bcfi.be (accessed July 2018).
58 Wang SY, Yang ZJ, Zhang L. Olanzapine
for preventing nausea and vomiting induced
by moderately and highly emetogenic
chemotherapy. Asian Pac J Cancer Prev
2014;15(22):9587–92.
59 DeRemer DL et al. Emerging role of
olanzapine for prevention and treatment of
chemotherapy-induced nausea and vomiting.
Pharmacotherapy 2016;36(2):218–29.
60 Yang T et al. Efficacy of olanzapine for the
prophylaxis of chemotherapy-induced nausea
and vomiting: a meta-analysis. Br J Clin
Pharmacol 2017;83(7):1369–79.
61 Navari RM et al. Olanzapine for the
prevention of chemotherapy-induced nausea
and vomiting. N Engl J Med 2016;375:134–42.
62 Bosnjak SM, Dimitrijevic J, Djordjevic F.
Cancer and chemotherapy-induced nausea
and vomiting: a focus on olanzapine. Curr Opin
Support Palliat Care 2016:10(2):180–8.
63 Yanai T et al .A double-blind randomized
phase II dose-finding study of olanzapine
10mg or 5mg for the prophylaxis of emesis
induced by highly emetogenic cisplatin-based
chemotherapy. Int J Clin Oncol 2018;23(2):382–8.
64 Nakashima K et al. A Phase II study of
palonosetron, aprepitant, dexamethasone and
olanzapine for the prevention of cisplatin-based
chemotherapy-induced nausea and vomiting in
patients with thoracic malignancy. Jpn J Clin
68 | 2019 | hospitalpharmacyeurope.com
Oncol 2017;47(9):840–3.
65 Aapro M et al. Preventing chemotherapy-
induced nausea and vomiting with netupitant/
palonosetron, the first fixed combination
antiemetic: current and future perspective.
Future Oncol 2019;15(10):1067–84.
66 Badowski ME. A review of oral cannabinoids
and medical marijuana for the treatment of
chemotherapy-induced nausea and vomiting:
a focus on pharmacokinetic variability and
pharmacodynamics. Cancer Chemother
Pharmacol 2017;80(3):441–9.
67 Polito S et al. Safety and efficacy of nabilone
for acute chemotherapy-induced vomiting
prophylaxis in pediatric patients: A multicenter,
retrospective review. Pediatr Blood Cancer
2018;65(12):e27374.
68 Haniadka R et al. Zingiber officinale (ginger)
as an anti-emetic in cancer chemotherapy:
a review. J Altern Complement Med
2012;18(5):440–4.
69 Bossi P et al. A randomized, double-
blind, placebo-controlled, multicenter study
of a ginger extract in the management of
chemotherapy-induced nausea and vomiting
(CINV) in patients receiving high-dose cisplatin.
Ann Oncol 2017;28(10):2547–51.
70 Konmun J et al. A phase II randomized
double-blind placebo-controlled study of
6-gingerol as an anti-emetic in solid tumor
patients receiving moderately to highly
emetogenic chemotherapy. Med Oncol
2017;34(4):69.
71 Chang WP, Peng YX. Does the oral
administration of ginger reduce chemotherapy-
induced nausea and vomiting? A Meta-
analysis of 10 randomized controlled trials.
Cancer Nurs 2018;Oct 6: doi: 10.1097/
NCC.0000000000000648.
72 Schwartzberg L et al. Phase III safety study
of intravenous NEPA: a novel fixed antiemetic
combination of fosnetupitant and palonosetron
in patients receiving highly emetogenic
chemotherapy. Ann Oncol 2018;29(7):1535–40.